BrainStorm Q3 net loss $6.9M; FDA refuses to file NurOwn BLA for ALS

BRAINSTORM CELL THERAPEUTICS INC.

Cash & short-term deposits $7.4M as of Sep 30, down from $12.2M on Jun 30.
Net loss $6.9M in Q3 2022 vs $5.3M in Q3 2021; EPS -$0.19 vs -$0.15.
FDA refused to file new BLA for NurOwn in ALS; company plans to request Type A meeting.
Phase 3 ALS post-hoc analyses at NEALS meeting addressed ALSFRS-R floor effect.
Phase 2 progressive MS trial results published showing safety and preliminary efficacy.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022, was approximately $6.9 million, EPS Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19.

Period: the third quarter ended September 30, 2022
Net income: Net loss for the three months ended September 30, 2022, was approximately $6.9 million
EPS: Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19
Result: reported results

Exact text from the filing

Net loss for the three months ended September 30, 2022, was approximately $6.9 million, as compared to a net loss of approximately $5.3 million for the three months ended September 30, 2021. Net loss per share for the three months ended September 30, 2022, and 2021 was $0.19 and $0.15, respectively.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-117689

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.